Sherif I F Badawy

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation
    Sherif I F Badawy
    Drug Product Science and Technology, Bristol Myers Squibb Company, One Squibb Drive, New Brunswick, NJ 08903, USA
    Int J Pharm 439:324-33. 2012
  2. ncbi Effect of processing and formulation variables on the stability of a salt of a weakly basic drug candidate
    Sherif Badawy
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, New Brunswick, New Jersey 08903, USA
    Pharm Dev Technol 9:239-45. 2004
  3. ncbi Effect of starting material particle size on its agglomeration behavior in high shear wet granulation
    Sherif I Farag Badawy
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ, USA
    AAPS PharmSciTech 5:e38. 2004
  4. ncbi A study on the effect of wet granulation on microcrystalline cellulose particle structure and performance
    Sherif I Farag Badawy
    Pharmaceutical Research Institute, Bristol Myers Squibb Co, One Squibb Drive, New Brunswick, New Jersey, 08903, USA
    Pharm Res 23:634-40. 2006
  5. ncbi Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389
    Sherif I Farag Badawy
    Pharmaceutical Research Institute, Bristol Myers Squibb Co, One Squibb Drive, New Brunswick, New Jersey 08903, USA
    Pharm Res 23:989-96. 2006
  6. ncbi Degradation pathways of a corticotropin-releasing factor antagonist in solution and solid states
    S Badawy
    Pharmaceutical Development, Bristol Myers Squibb Company, One Squibb Dr, New Brunswick, New Jersey 08903, USA
    J Pharm Sci 98:2636-47. 2009
  7. ncbi Effect of spray-dried mannitol on the performance of microcrystalline cellulose-based wet granulated tablet formulation
    Sherif I F Badawy
    Bristol Myers Squibb Company, Pharmaceutics R and D, New Brunswick, New Jersey 08903, USA
    Pharm Dev Technol 15:339-45. 2010
  8. ncbi Microenvironmental pH modulation in solid dosage forms
    Sherif I Farag Badawy
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey, USA
    J Pharm Sci 96:948-59. 2007
  9. ncbi Assessment of segregation potential of powder blends
    Keyur R Shah
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ 08903, USA
    Pharm Dev Technol 12:457-62. 2007

Detail Information

Publications9

  1. ncbi Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation
    Sherif I F Badawy
    Drug Product Science and Technology, Bristol Myers Squibb Company, One Squibb Drive, New Brunswick, NJ 08903, USA
    Int J Pharm 439:324-33. 2012
    ..Understanding the impact of primary granule properties on bulk powder properties and final product critical quality attributes provides the basis for modulating granulation parameters in order to optimize product performance...
  2. ncbi Effect of processing and formulation variables on the stability of a salt of a weakly basic drug candidate
    Sherif Badawy
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, New Brunswick, New Jersey 08903, USA
    Pharm Dev Technol 9:239-45. 2004
    ..This study shows that selection of the proper manufacturing process, in conjunction with the appropriate pH modifier, could be critical to dosage form stability...
  3. ncbi Effect of starting material particle size on its agglomeration behavior in high shear wet granulation
    Sherif I Farag Badawy
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ, USA
    AAPS PharmSciTech 5:e38. 2004
    ..The lower yield stress of compacts prepared with this grade may indicate a higher coalescence tendency for its granules during wet granulation...
  4. ncbi A study on the effect of wet granulation on microcrystalline cellulose particle structure and performance
    Sherif I Farag Badawy
    Pharmaceutical Research Institute, Bristol Myers Squibb Co, One Squibb Drive, New Brunswick, New Jersey, 08903, USA
    Pharm Res 23:634-40. 2006
    ..The aim of this study was to investigate the mechanism of the effect of wet granulation process on the compaction properties of microcrystalline cellulose (MCC)...
  5. ncbi Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389
    Sherif I Farag Badawy
    Pharmaceutical Research Institute, Bristol Myers Squibb Co, One Squibb Drive, New Brunswick, New Jersey 08903, USA
    Pharm Res 23:989-96. 2006
    ....
  6. ncbi Degradation pathways of a corticotropin-releasing factor antagonist in solution and solid states
    S Badawy
    Pharmaceutical Development, Bristol Myers Squibb Company, One Squibb Dr, New Brunswick, New Jersey 08903, USA
    J Pharm Sci 98:2636-47. 2009
    ..This intermediate was observed at a lower concentration in the tablet at the high humidity conditions and at very low concentrations in acidic solutions...
  7. ncbi Effect of spray-dried mannitol on the performance of microcrystalline cellulose-based wet granulated tablet formulation
    Sherif I F Badawy
    Bristol Myers Squibb Company, Pharmaceutics R and D, New Brunswick, New Jersey 08903, USA
    Pharm Dev Technol 15:339-45. 2010
    ..Presence of mannitol in the formulation reduced the compression speed sensitivity and also decreased the susceptibility of the formulation to hardness loss upon storage...
  8. ncbi Microenvironmental pH modulation in solid dosage forms
    Sherif I Farag Badawy
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey, USA
    J Pharm Sci 96:948-59. 2007
    ..The incorporation of acidic pH modifiers in the controlled release formulation increases the solubility of the basic drug even as the high pH dissolution medium enters into the dosage form hence increasing drug release rate...
  9. ncbi Assessment of segregation potential of powder blends
    Keyur R Shah
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ 08903, USA
    Pharm Dev Technol 12:457-62. 2007
    ..A segregation risk classification system is proposed to assess the potential of segregation at large scale...